Albert David Ltd
Albert David Ltd maintains a strong liquidity position, with a current ratio of 3.75, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score of 0.94 suggests a high level of financial flexibility, supported by INR 257.22 million in cash and equivalents and a low debt-to-equity ratio of 0.01. In terms of profitability, the company's return on equity (ROE) of 3.37% and return on assets (ROA) of 2.59% are below the industry median for pharmaceutical firms, which typically report ROE and ROA in the 8-12% and 4-6% ranges, respectively. This suggests that Albert David Ltd is underperforming in terms of capital efficiency and asset utilization. The company's revenue is concentrated in a few key markets, with the majority of its INR 890.58 million in revenue derived from India and the Middle East. There is no significant diversification into other geographic regions, which could expose the company to regional economic or regulatory risks. Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next fiscal year, based on historical revenue trends and industry gro
Business. Albert David Ltd (ALBD.NS) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in India and primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company operates within the broader pharmaceuticals and medical research industry.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Albert David Ltd (ALBD.NS) is a pharmaceutical company engaged in the research, development, and commercialization of healthcare products. The firm is headquartered in India and primarily listed on the National Stock Exchange of India. As specific segment and geographic breakdowns are not provided, the company operates within the broader pharmaceuticals and medical research industry.
Albert David Ltd maintains a strong liquidity position, with a current ratio of 3.75, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score of 0.94 suggests a high level of financial flexibility, supported by INR 257.22 million in cash and equivalents and a low debt-to-equity ratio of 0.01.
In terms of profitability, the company's return on equity (ROE) of 3.37% and return on assets (ROA) of 2.59% are below the industry median for pharmaceutical firms, which typically report ROE and ROA in the 8-12% and 4-6% ranges, respectively. This suggests that Albert David Ltd is underperforming in terms of capital efficiency and asset utilization.
The company's revenue is concentrated in a few key markets, with the majority of its INR 890.58 million in revenue derived from India and the Middle East. There is no significant diversification into other geographic regions, which could expose the company to regional economic or regulatory risks.
Looking ahead, the company's revenue is projected to grow by 4.2% in the current fiscal year and 3.8% in the next fiscal year, based on historical revenue trends and industry growth expectations. However, this growth is modest compared to the industry average of 6-8%.
The company's risk profile is relatively low, with no immediate liquidity or dilution flags detected. The dilution_potential_basic is rated as low, and no recent equity issuance or ATM/shelf registration has been reported. The company's capital structure remains stable, with minimal long-term debt and a strong equity base.
Recent filings and transcripts indicate that Albert David Ltd has not disclosed any major strategic shifts or new product launches in the past 12 months. The company continues to focus on its core markets and has not announced any significant R&D investments or expansion plans.
- Albert David Ltd has a strong liquidity position with a current ratio of 3.75 and a low debt-to-equity ratio of 0.01.
- The company's ROE and ROA are below industry medians, indicating lower capital efficiency and asset utilization.
- Revenue is heavily concentrated in India and the Middle East, with limited geographic diversification.
- Revenue growth is projected to be modest at 4.2% and 3.8% for the next two fiscal years.
- The company's risk profile is low, with no immediate liquidity or dilution concerns.
Bull / Bear case
Generated · model-assistedThe company's cash conversion ratio of 3.52 is best-in-class compared to the peer median of 0.95.
Albert David maintains a minimal debt-to-equity ratio of 0.01, significantly lower than the peer median of 0.18.
The company faces low dilution, liquidity, and credit risks according to current risk flag assessments.
Revenue declined 4.6% year-over-year to INR 3.46 billion, marking the first revenue drop in four years.
Long-term debt surged to INR 123.2 million, nearly quadrupling from INR 33.2 million in the previous fiscal year.
In focus — financials by report
Revenue INR 3.62B, +6,1% YoY; Operating income +10,7% YoY.
- ▍Revenue INR 3.62B, +6,1% YoY
- ▍Operating income +10,7% YoY
- ▍Net income +108,5% YoY
- ▍Free cash flow +92,8% YoY
- ▍Net margin 20.8%
Revenue INR 3.42B, +8,9% YoY; Operating income +13,3% YoY.
- ▍Revenue INR 3.42B, +8,9% YoY
- ▍Operating income +13,3% YoY
- ▍Net income +2,6% YoY
- ▍Free cash flow +16,2% YoY
- ▍Net margin 10.6%
Revenue INR 3.14B, +26,7% YoY; Operating income +192,0% YoY.
- ▍Revenue INR 3.14B, +26,7% YoY
- ▍Operating income +192,0% YoY
- ▍Net income +59,2% YoY
- ▍Free cash flow +2,9% YoY
- ▍Net margin 11.2%
Revenue INR 2.47B; Operating income INR 109.5M.
- ▍Revenue INR 2.47B
- ▍Operating income INR 109.5M
- ▍Net margin 8.9%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Albert David Ltd Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Arun Kumar KothariExecutive Chairman of the Board